Italia markets closed

Biocartis Group NV (0R72.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
1,7340+0,0143 (+0,83%)
Alla chiusura: 04:40PM GMT

Biocartis Group NV

Generaal de Wittelaan 11 B
Mechelen 2800
Belgium
32 1 563 20 00
https://www.biocartis.com

Settore/i
Settore
Impiegati a tempo pieno619

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Herman VerrelstCEO & Exec. Director434,91kN/D1974
Mr. Jean-Marc RoelandtChief Financial OfficerN/DN/D1965
Mr. Piet HouwenChief Operating OfficerN/DN/D1968
Mr. Benoit DevogelaereChief Technology OfficerN/DN/D1981
Mr. Geert Maertens Ph.D.Chairman of Scientific Advisory Board & Chief Scientific OfficerN/DN/DN/D
Renate DegraveHead of IR & Corp. CommunicationsN/DN/DN/D
Ms. Susy SpruytHead of People & OrganizationN/DN/D1968
Dr. Erwin SablonHead of R&D and Alliance ManagementN/DN/D1965
Mr. Reginald Van GenechtenHead of Manufacturing & Supply ChainN/DN/D1966
Mr. Dirk ZimmermannGlobal Head of Pharma Collaborations & PartneringN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.

Governance aziendale

L'ISS Governance QualityScore di Biocartis Group NV al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.